MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ibd/izae152

Медицинская библиотека · Inflammatory bowel diseases · 2025

Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.

Argüelles-Arias Federico, Rodriguez González F Javier, González Antuña Jaime, Castro Laria Luisa, Gutiérrez Martinez Fernando, Alcaín Martinez Guillermo, Maldonado Pérez Belén, Camargo Camero Raquel, Martos Van Dussen J Victor, Fernández Castañer Alejandra, Valdés Delgado Teresa

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Ustekinumab (UST) is commonly used to treat Crohn's disease and ulcerative colitis. However, some patients may experience diminishing response or require increased dosage. Intravenous (IV) UST maintenance is explored as a solution.

OBJECTIVES

We sought to evaluate IV UST maintenance effectiveness and safety in inflammatory bowel disease patients with partial or lost subcutaneous UST response.

METHODS

This was a multicenter retrospective study of inflammatory bowel disease patients on IV UST maintenance. Clinical response and remission at weeks 12 and 52, defined as Harvey-Bradshaw Index ≤4 for Crohn's disease or partial Mayo score ≤2 for ulcerative colitis. Objective markers reduction (fecal calprotectin, C-reactive protein), UST trough levels pre- and post-IV maintenance, and adverse events were assessed.

RESULTS

A total of 59 patients were included. Clinical remission at weeks 12 and 52 achieved by 47.5% and 64.3% respectively. 96.6% continued IV UST at follow-up. UST serum levels quadrupled. No adverse events reported.

CONCLUSIONS

IV UST maintenance effectively sustained remission in most patients at 52 weeks.

Для цитирования: Argüelles-Arias Federico, Rodriguez González F Javier, González Antuña Jaime, Castro Laria Luisa, Gutiérrez Martinez Fernando, Alcaín Martinez Guillermo, Maldonado Pérez Belén, Camargo Camero Raquel, Martos Van Dussen J Victor, Fernández Castañer Alejandra, Valdés Delgado Teresa. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.. Inflammatory bowel diseases. 2025. DOI: 10.1093/ibd/izae152.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.